IGC Pharma opened lower at $0.19, compared with its previous close of $0.20. In the last trading session, the stock traded between $0.18 and $0.19. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in IGC Pharma is now worth
$ 13.01
Resulting in a loss of
$ 86.99 (86.99%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.01 (-6.49%)
Day High
$0.19
Day Low
$0.18
Day Open
$0.19
Prev Close
$0.20
Volume
3,59,576
1W Return
-2.62%
1M Return
-32.61%
3M Return
-33.81%
6M Return
-38.61%
1Y Return
-51.90%
Fundamentals
Market Cap ($ Mn)
22
PE Ratio
-
PB Ratio
5.18
PEG Ratio
-
ROE
-101.25%
ROCE
-98.51%
EPS (TTM)
$-0.03
Investment Returns
1 Week
-2.62%
1 Month
-32.61%
3 Months
-33.81%
6 Months
-38.61%
9 Months
-26.19%
Financials
Quarterly
All values in $ Mn
0.3
Dec 24
0.3
Mar 25
0.3
Jun 25
0.2
Sep 25
0.3
Mar 26
0.3
Jun 26
Updates
17Aug
IGC Pharma Q2 Results: Sales up 39% YoY, EPS loss widens to $(0.03)
IGC Pharma's Q2 results show a mixed bag with strong top-line performance but weak bottom-line execution. Sales reached $265,000, beating estimates and rising 38.74% YoY. Conversely, EPS loss widened to $(0.03), missing estimates by 50% and worsening from the prior year's $(0.02) loss.
2mo ago
29Jul
IGC Pharma evaluates recovery options after jury verdict
IGC Pharma is assessing civil remedies after Andrew Left was found guilty of securities fraud linked to a 2018 short campaign. The indictment alleges the campaign generated over $4.9 million in combined profits for Left and a hedge fund. The company will determine if recoverable damages exist for market, reputational, and operational harm while continuing its Phase 2 CALMA trial for Alzheimer's disease.
3mo ago
8Jul
IGC Pharma execs buy 4.27M shares to settle $1.15M debt
IGC Pharma executives Ram Mukunda and Claudia Grimaldi purchased 4,274,853 shares at $0.27 each to cancel $1.15 million in debts, including over $552,362 in personal cash advances. The shares were issued as restricted securities under Section 4(a)(2) and approved by independent directors.
4mo ago
23Jun
IGC Pharma launches AI platform to accelerate Alzheimer's research
IGC Pharma has released the beta version of its Agentic Harmonization Assistant, an AI platform aimed at harmonizing fragmented biomedical data to accelerate Alzheimer's research. The patent-pending technology supports the company's Phase 2 candidate IGC-AD1 and expands into imaging and omics applications. A demonstration of the platform is scheduled for AAIC 2026 in London.
4mo ago
11Jun
IGC Pharma reaches 146-patient target in Phase 2 CALMA trial
IGC Pharma, Inc. achieved the target enrollment of 146 patients for its Phase 2 CALMA trial of IGC-AD1, targeting agitation in Alzheimer's dementia. The company will continue limited over-enrollment to mitigate attrition and strengthen the dataset. CEO Ram Mukunda highlighted the milestone as a critical step toward generating robust data for topline analysis.
